ReNeuron firms up commitment to retinal diseases with Schepens Institute
This article was originally published in Scrip
Executive Summary
ReNeuron has further built on its existing collaboration with the Schepens Eye Research Institute in Boston, US, by signing a patent and know-how licence agreement concerning the company’s ReN003 stem cell therapy programme in retinal diseases.